Suzanne George, MD
While chemotherapeutic approaches are available for patients with uterine sarcomas, research is moving in the direction of novel combinations, biomarkers, and collaboration, explained Suzanne George, MD.
State of the Science Summit™ on Ovarian Cancer, George highlighted the available therapies for patients with uterine sarcomas and what novel options are on the horizon.
OncLive: What is the current state of uterine sarcoma management?
: [At the State of the Science Summit™] I discussed systemic therapies in uterine leiomyosarcoma, specifically the role of chemotherapy in patients with advanced or metastatic disease. A key point is that there is an increasing number of systemic options available for patients with this disease, with a number of new approvals over the last several years and some promising agents that are currently under development.
As a field, there is a tremendous opportunity for collaboration between gynecologic oncology and sarcoma medical oncology to build bridges around what we understand—around what we need to learn, so that we can come together as a community, fundamentally, with patients at the center.
Could you expand on some of the available options?
Recent studies have suggested that gemcitabine-/docetaxel-based regimens, as well as anthracycline-based regimens, have activity in this disease. It is not about which one is better, per se, but women should know that there are multiple options available to them. [For example] olaratumab, a novel PDGFR-α antibody, was approved over the last couple of years in both the United States and in Europe. Again, it really highlights the importance of collaboration and communication in this field.
... to read the full story